Subject(s)
3' Untranslated Regions/genetics , DNA Mutational Analysis/methods , Genetic Testing/methods , Oxidoreductases Acting on CH-NH Group Donors/genetics , Point Mutation , Polymerase Chain Reaction/methods , Polymorphism, Genetic , Prothrombin/genetics , Thrombophilia/genetics , Alleles , Automation , DNA Mutational Analysis/instrumentation , Genetic Testing/instrumentation , Humans , Methylenetetrahydrofolate Reductase (NADPH2) , Polymerase Chain Reaction/instrumentation , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Taq Polymerase , Thrombophilia/diagnosis , Thrombophilia/epidemiology , Time FactorsABSTRACT
The G1691A (Leiden) mutation of the factor V gene is the most prevalent identified cause of venous thrombosis. Therefore, we developed a new genetic test using the TaqMan system. With this assay which combines PCR amplification and detection reaction in one closed tube, a cohort of 234 patients with a history of thrombosis was screened. In parallel, amplification products of the same patients were screened with a previously described test using endonuclease digestion of PCR products followed by gel electrophoresis. Identical results were obtained by both methods. Among cases, 122 (52%) individuals were homozygous normal, 99 (42%) were heterozygous affected and 13 (5.5%) showed homozygous pattern for the Factor V Leiden mutation. Thus, it could be demonstrated that the new TaqMan assay is a robust, rapid and automated method for high throughput application which avoids time consuming and difficult post-PCR steps.
